Publications

Detailed Information

Prestroke antiplatelet effect on symptomatic intracranial hemorrhage and functional outcome in intravenous thrombolysis

DC Field Value Language
dc.contributor.authorChoi, Jay Chol-
dc.contributor.authorLee, Ji Sung-
dc.contributor.authorPark, Tai Hwan-
dc.contributor.authorCho, Yong-Jin-
dc.contributor.authorPark, Jong-Moo-
dc.contributor.authorKang, Kyusik-
dc.contributor.authorLee, Kyung Bok-
dc.contributor.authorLee, Soo Joo-
dc.contributor.authorKim, Jae Guk-
dc.contributor.authorLee, Jun-
dc.contributor.authorPark, Man-Seok-
dc.contributor.authorChoi, Kang-Ho-
dc.contributor.authorKim, Joon-Tae-
dc.contributor.authorYu, Kyung-Ho-
dc.contributor.authorLee, Byung-Chul-
dc.contributor.authorOh, Mi-Sun-
dc.contributor.authorCha, Jae-Kwan-
dc.contributor.authorKim, Dae-Hyun-
dc.contributor.authorNah, Hyun-Wook-
dc.contributor.authorKim, Dong-Eog-
dc.contributor.authorRyu, Wi-Sun-
dc.contributor.authorKim, Beom Joon-
dc.contributor.authorBae, Hee-Joon-
dc.contributor.authorKim, Wook-Joo-
dc.contributor.authorShin, Dong-Ick-
dc.contributor.authorYeo, Min-Ju-
dc.contributor.authorIl Sohn, Sung-
dc.contributor.authorHong, Jeong-Ho-
dc.contributor.authorLee, Juneyoung-
dc.contributor.authorHong, Keun-Sik-
dc.date.accessioned2024-08-08T01:35:46Z-
dc.date.available2024-08-08T01:35:46Z-
dc.date.created2018-09-10-
dc.date.created2018-09-10-
dc.date.issued2016-09-
dc.identifier.citationJournal of Stroke, Vol.18 No.3, pp.344-351-
dc.identifier.issn2287-6391-
dc.identifier.urihttps://hdl.handle.net/10371/206882-
dc.description.abstractBackground and Purpose About 30%-40% of stroke patients are taking antiplatelet at the time of their strokes, which might increase the risk of symptomatic intracranial hemorrhage (SICH) with intravenous tissue plasminogen activator (IV-TPA) therapy. We aimed to assess the effect of pre stroke antiplatelet on the SICH risk and functional outcome in Koreans treated with IV-TPA. Methods From a prospective stroke registry, we identified patients treated with IV-TPA between October 2009 and November 2014. Prestroke antiplatelet use was defined as taking antiplatelet within 7 days before the stroke onset. The primary outcome was SIGH. Secondary outcomes were discharge modified Rankin Scale (mRS) score and in-hospital mortality. Results Of 1,715 patients treated with IV-TPA, 441 (25.7%) were on prestroke antiplatelet. Pre-stroke antiplatelet users versus non-users were more likely to be older, to have multiple vascular risk factors. Prestroke antiplatelet use was associated with an increased risk of SICH (5.9% vs. 3.0%; adjusted odds ratio [OR] 1.79 [1.05-3.04]). However, at discharge, the two groups did not differ in mRS distribution (adjusted OR 0.90 [0.72-1.14]), mRS 0-1 outcome (34.2% vs. 33.7%; adjusted OR 1.27 [0.94-1.72), mRS 0-2 outcome (52.4% vs. 52.9%; adjusted OR 1.21 [0.90-1.63]), and in-hospital mortality (6.1% vs. 4.2%; adjusted OR 1.19 [0.71-2.01]). Conclusions Despite an increased risk of SICH, prestroke antiplatelet users compared to non-users had comparable functional outcomes and in-hospital mortality with IV-TPA therapy. Our results support the use of IV-TPA in eligible patients taking antiplatelet therapy before their stroke onset.-
dc.language영어-
dc.publisher대한뇌졸중학회-
dc.titlePrestroke antiplatelet effect on symptomatic intracranial hemorrhage and functional outcome in intravenous thrombolysis-
dc.typeArticle-
dc.identifier.doi10.5853/jos.2016.00185-
dc.citation.journaltitleJournal of Stroke-
dc.identifier.wosid000385335500013-
dc.identifier.scopusid2-s2.0-84990070376-
dc.citation.endpage351-
dc.citation.number3-
dc.citation.startpage344-
dc.citation.volume18-
dc.identifier.kciidART002150810-
dc.description.isOpenAccessY-
dc.contributor.affiliatedAuthorBae, Hee-Joon-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusACUTE ISCHEMIC-STROKE-
dc.subject.keywordPlusTISSUE-PLASMINOGEN-ACTIVATOR-
dc.subject.keywordPlusRANDOMIZED CONTROLLED-TRIALS-
dc.subject.keywordPlusINTRACEREBRAL HEMORRHAGE-
dc.subject.keywordPlusRISK-FACTORS-
dc.subject.keywordPlusTHERAPY-
dc.subject.keywordPlusMETAANALYSIS-
dc.subject.keywordPlusMULTICENTER-
dc.subject.keywordPlusADJUSTMENT-
dc.subject.keywordPlusREGISTRY-
dc.subject.keywordAuthorStroke-
dc.subject.keywordAuthorThrombolytic therapy-
dc.subject.keywordAuthorPlatelet aggregation inhibitors-
dc.subject.keywordAuthorOutcome assessment-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Related Researcher

  • College of Medicine
  • Department of Medicine
Research Area 뇌경색, 뇌졸중, 혈관성 인지장애 및 치매

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share